Genmab A/S (GMAB) Reports Q3 Net DARZALEX Sales of $2.5B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
October 17, 2023 6:22 AM EDTCompany Announcement
Net sales of DARZALEX® in the third quarter of 2023 totaled USD 2,499 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)COPENHAGEN, Denmark; October 17, 2023 Genmab A/S (Nasdaq: GMAB) announced today that worldwide... More
